Latest Trade News and Agreements: June 2022
Sustainability Update: June 2022
May 2022 INC Updates & News Brief
2022 Australian Almond Conference
Save the date for the 2022 Australian Almond conference! Come and join us at Adelaide Convention Centre, 10 – 12 October 2022. More details to follow. Event web
Cranberry Consumption May Help Protect Against Cognitive Decline
Research on Remission of Peanut Allergies in Children
Remission of peanut allergy is associated with rewiring of allergen-driven T helper 2-related gene networks
Background: The immunological changes underpinning acquisition of remission (also called sustained unresponsiveness) following food immunotherapy remain poorly defined. Limited access to effective therapies and biosamples from treatment responders has prevented progress. Probiotic peanut oral immunotherapy is highly effective at inducing remission, providing an opportunity to investigate immune changes. Methods: Using a systems biology approach, we […]
Chronic Consumption of Cranberries (Vaccinium macrocarpon) for 12 Weeks Improves Episodic Memory and Regional Brain Perfusion in Healthy Older Adults: A Randomised, Placebo-Controlled, Parallel-Groups Feasibility Study.
Background: Ageing is highly associated with cognitive decline and modifiable risk factors such as diet are believed to protect against this process. Specific dietary components and in particular, (poly)phenol-rich fruits such as berries have been increasingly recognised for their protection against age-related neurodegeneration. However, the impact of cranberries on cognitive function and neural functioning in older […]
The natural history of peanut and egg allergy in children up to age 6 years in the HealthNuts population-based longitudinal study.
Background: Prospectively collected data on the natural history of food allergy are lacking. Objective: We examined the natural history of egg and peanut allergy in children from age 1 to 6 years and assessed whether a skin prick test (SPT) result or other clinical factors at diagnosis are associated with the persistence or resolution of food allergy […]
Efficacy and safety of oral immunotherapy in children aged 1-3 years with peanut allergy (the Immune Tolerance Network IMPACT trial): a randomised placebo-controlled study.
Background: For young children with peanut allergy, dietary avoidance is the current standard of care. We aimed to assess whether peanut oral immunotherapy can induce desensitisation (an increased allergic reaction threshold while on therapy) or remission (a state of non-responsiveness after discontinuation of immunotherapy) in this population. Methods: We did a randomised, double-blind, placebo-controlled study in five […]